Association between SCAP and SREBF1 gene polymorphisms and metabolic syndrome in schizophrenia patients treated with atypical antipsychotics

References

• Alberti KG, Zimmet P, Shaw J. 2005. The metabolic syndrome-a new worldwide definition. Lancet. 366:1059–1062.
   PubMed Web of Science ®Google Scholar
• Bai YM, Chen TT, Liou YJ, Hong CJ, Tsai SJ. 2011. Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics. Schizophr Res. 125:179–186.
   PubMed Web of Science ®Google Scholar
• Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 21:263–265.
   PubMed Web of Science ®Google Scholar
• Bhattacharya BS, Sweby PK, Minihane AM, Jackson KG, Tindall MJ. 2014. A mathematical model of the sterol regulatory element binding protein 2 cholesterol biosynthesis pathway. J Theor Biol. 349:150–162.
   PubMed Web of Science ®Google Scholar
• Calvo SE, Tucker EJ, Compton AG, Kirby DM, Crawford G, Burtt NP, Rivas M, Guiducci C, Bruno DL, Goldberger OA, et al. 2010. High-throughput, pooled sequencing identifies mutations in NUBPL and FOXRED1 in human complex I deficiency. Nat Genet. 42:851–858.
   PubMed Web of Science ®Google Scholar
• Canfran-Duque A, Casado ME, Pastor O, Sanchez-Wandelmer J, de la Pena G, Lerma M, Mariscal P, Bracher F, Lasunción MA, Busto R. 2013. Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro. J Lipid Res. 54:310–324.
   PubMed Web of Science ®Google Scholar
• Chen Z, Ding Z, Ma G, Liu N, Qian Q. 2011. Sterol regulatory element-binding transcription factor (SREBF)-2, SREBF cleavage-activating protein (SCAP), and premature coronary artery disease in a Chinese population. Mol Biol Rep. 38:2895–2901.
   PubMed Web of Science ®Google Scholar
• Eberle D, Clement K, Meyre D, Sahbatou M, Vaxillaire M, Le Gall A, Ferré P, Basdevant A, Froguel P, Foufelle F. 2004. SREBF-1 gene polymorphisms are associated with obesity and type 2 diabetes in French obese and diabetic cohorts. Diabetes. 53:2153–2157.
   PubMed Web of Science ®Google Scholar
• Edwards PA, Tabor D, Kast HR, Venkateswaran A. 2000. Regulation of gene expression by SREBP and SCAP. Biochim Biophys Acta. 1529:103–113.
   PubMed Web of Science ®Google Scholar
• Fernø J, Raeder MB, Vik-Mo AO, Skrede S, Glambek M, Tronstad KJ, Breilid H, Løvlie R, Berge RK, Stansberg C, Steen VM. 2005. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J. 5:298–304.
   PubMed Web of Science ®Google Scholar
• Fernø J, Skrede S, Vik-Mo AO, Havik B, Steen VM. 2006. Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs. BMC Neurosci. 7:69.
   PubMed Web of Science ®Google Scholar
• Ferno J, Skrede S, Vik-Mo AO, Jassim G, Le Hellard S, Steen VM. 2011. Lipogenic effects of psychotropic drugs: focus on the SREBP system. Front Biosci (Landmark Ed). 16:49–60.
   PubMed Web of Science ®Google Scholar
• Fernø J, Vik-Mo AO, Jassim G, Håvik B, Berge K, Skrede S, Gudbrandsen OA, Waage J, Lunder N, Mørk S, et al. 2009. Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology (Berl). 203:73–84.
   PubMed Web of Science ®Google Scholar
• Gabriel S, Ziaugra L, Tabbaa D. 2009. SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet Chapter. 2:2–12.
   Google Scholar
• Gylling H, Hallikainen M, Kolehmainen M, Toppinen L, Pihlajamäki J, Mykkänen H, Agren JJ, Rauramaa R, Laakso M, Miettinen TA. 2007. Cholesterol synthesis prevails over absorption in metabolic syndrome. Transl Res. 149:310–316.
   PubMed Web of Science ®Google Scholar
• Hu Y, Kutscher E, Davies GE. 2010. Berberine inhibits SREBP-1-related clozapine and risperidone induced adipogenesis in 3T3-L1 cells. Phytother Res. 24:1831–1838.
   PubMed Web of Science ®Google Scholar
• Laaksonen R, Thelen KM, Päivä H, Matinheikki J, Vesalainen R, Janatuinen T, Knuuti J, Rontu R, von Bergmann K, Lütjohann D, Lehtimäki T. 2006. Genetic variant of the SREBF-1 gene is significantly related to cholesterol synthesis in man. Atherosclerosis. 185:206–209.
   PubMed Web of Science ®Google Scholar
• Laudes M, Barroso I, Luan J, Soos MA, Yeo G, Meirhaeghe A, Logie L, Vidal-Puig A, Schafer AJ, Wareham NJ, O’Rahilly S. 2004. Genetic variants in human sterol regulatory element binding protein-1c in syndromes of severe insulin resistance and type 2 diabetes. Diabetes. 53:842–846.
   PubMed Web of Science ®Google Scholar
• Lauressergues E, Martin F, Helleboid A, Bouchaert E, Cussac D, Bordet R, Hum D, Luc G, Majd Z, Staels B, et al. 2011. Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver. Naunyn Schmiedebergs Arch Pharmacol. 383:423–436.
   PubMed Web of Science ®Google Scholar
• Lauressergues E, Staels B, Valeille K, Majd Z, Hum DW, Duriez P, Cussac D. 2010. Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes. Naunyn Schmiedebergs Arch Pharmacol. 381:427–439.
   PubMed Web of Science ®Google Scholar
• Le Hellard S, Muhleisen TW, Djurovic S, Fernø J, Ouriaghi Z, Mattheisen M, Vasilescu C, Raeder MB, Hansen T, Strohmaier J, et al. 2010. Polymorphisms in SREBF1 and SREBF2, two antipsychotic-activated transcription factors controlling cellular lipogenesis, are associated with schizophrenia in German and Scandinavian samples. Mol Psychiatry. 15:463–472.
   PubMed Web of Science ®Google Scholar
• Le Hellard S, Theisen FM, Haberhausen M, Raeder MB, Fernø J, Gebhardt S, Hinney A, Remschmidt H, Krieg JC, Mehler-Wex C, et al. 2009. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects? Mol Psychiatry. 14:308–317.
   PubMed Web of Science ®Google Scholar
• Lett TA, Wallace TJ, Chowdhury NI, Tiwari AK, Kennedy JL, Muller DJ. 2012. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry. 17:242–266.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang Z, He Z, Tang W, Li T, Zeng Z, He L, Shi Y. 2009. A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell Res. 19:519–523.
   PubMed Web of Science ®Google Scholar
• Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. 2013. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis. Schizophr Bull. 39:306–318.
   PubMed Web of Science ®Google Scholar
• Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffren EL, Eisenberg MJ. 2010. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 56:1113–1132.
   PubMed Web of Science ®Google Scholar
• Muller DJ, Chowdhury NI, Zai CC. 2013. The pharmacogenetics of antipsychotic-induced adverse events. Curr Opin Psychiatry. 26:144–150.
   PubMed Web of Science ®Google Scholar
• Raeder MB, Ferno J, Vik-Mo AO, Steen VM. 2006. SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects? Mol Cell Biochem 289:167–173.
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Kirk SL. 2010. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Ther 125:169–179.
   PubMed Web of Science ®Google Scholar
• Risselada AJ, Vehof J, Bruggeman R, Wilffert B, Cohen D, Al Hadithy AF, Arends J, Mulder H. 2012. Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study. Pharmacogenomics J. 12:62–67.
   PubMed Web of Science ®Google Scholar
• Rojas GP, Poblete AC, Orellana GX, Rouliez AK, Liberman GC. 2009. [Atypical antipsychotic induced weight gain and metabolic disorders]. Rev Med Chil. 137:106–114.
   PubMed Web of Science ®Google Scholar
• Salek L, Lutucuta S, Ballantyne CM, Gotto JA, Marian AJ. 2002. Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin. J Mol Med (Berl). 80:737–744.
   PubMed Web of Science ®Google Scholar
• Shao W, Espenshade PJ. 2014. Sterol regulatory element-binding protein (SREBP) cleavage regulates golgi-to-ER recycling of SREBP cleavage activating protein (SCAP). J Biol Chem. 289:7547–7557.
   PubMed Web of Science ®Google Scholar
• Shi YY, He L. 2005. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 15:97–98.
   PubMed Web of Science ®Google Scholar
• Vassas TJ, Burghardt KJ, Ellingrod VL. 2014. Pharmacogenomics of sterol synthesis and statin use in schizophrenia subjects treated with antipsychotics. Pharmacogenomics. 15:61–67.
   PubMed Web of Science ®Google Scholar
• Westra HJ, Peters MJ, Esko T, Yaghootkar H, Westra HJ, Peters M, Schurmann C, Kettunen J, Christiansen MW, Fairfax BP et al. 2013. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat Genet. 45:1238–1243.
   PubMed Web of Science ®Google Scholar
• Wysokinski A, Kowman M, Kloszewska I. 2012. The prevalence of metabolic syndrome and Framingham cardiovascular risk scores in adult inpatients taking antipsychotics - a retrospective medical records review. Psychiatr Danub. 24:314–322.
   PubMed Web of Science ®Google Scholar
• Yang L, Chen J, Liu D, Yu S, Cong E, Li Y, Wu H, Yue Y, Zuo S, Wang Y, et al. 2015. Association between SREBF2 gene polymorphisms and metabolic syndrome in clozapine-treated patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 56:136–141.
   PubMed Web of Science ®Google Scholar
• Yang LH, Chen TM, Yu ST, Chen YH. 2007. Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells. Pharmacol Res. 56:202–208.
   PubMed Web of Science ®Google Scholar
• Yang T, Goldstein JL, Brown MS. 2000. Overexpression of membrane domain of SCAP prevents sterols from inhibiting SCAP.SREBP exit from endoplasmic reticulum. J Biol Chem. 275:29881–29886.
   PubMed Web of Science ®Google Scholar